Patents by Inventor Ekkehard Mössner

Ekkehard Mössner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE
    Publication number: 20180291110
    Abstract: The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 18, 2017
    Publication date: October 11, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Julia KRUEGER, Ekkehard MOESSNER, Jens NIEWOEHNER
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20180282399
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: December 28, 2017
    Publication date: October 4, 2018
    Inventors: Ulrich BRINKMANN, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • HUMANIZED ANTI-HUMAN CD19 ANTIBODIES AND METHODS OF USE
    Publication number: 20180282409
    Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Guy GEORGES, Alexander HAAS, Hubert KETTENBERGER, Ekkehard MOESSNER, Tilman SCHLOTHAUER, Michael MOLHOJ, Laurent LARIVIERE
  • ASPGR antibodies and uses thereof
    Patent number: 10087254
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: October 2, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Thomas Hofer, Changhua Ji, Ekkehard Moessner, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20180273643
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 27, 2018
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane Neumann, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Bispecific antibodies against CD3 and BCMA
    Patent number: 10077315
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 18, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITY
    Publication number: 20180230215
    Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 16, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Claudia FERRARA KOLLER, Ekkehard MOESSNER, Mi HE
  • METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA
    Publication number: 20180222991
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Minh Diem VU, Klaus STREIN, Ekkehard MOESSNER, Ralf HOSSE, Oliver AST, Anne FREIMOSER-GRUNDSCHOBER, Marina BACAC, Tanja FAUTI, Christian KLEIN, Pablo UMANA, Samuel Moser
  • Interleukin-10 fusion proteins and uses thereof
    Patent number: 10040843
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 7, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20180142037
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Applicant: Roche Glycart AG
    Inventors: Oliver AST, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Trimeric antigen binding molecules
    Patent number: 9975958
    Abstract: The present invention pertains to a trimeric antigen binding molecule comprising three fusion polypeptides, each comprising at least one antigen binding moiety fused to a trimerization domain derived from human cartilage matrix protein. In addition, the present invention relates to polynucleotides encoding such trimeric antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the trimeric antigen binding molecules of the invention, and to methods of using these trimeric antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 22, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Ekkehard Moessner, Pablo Umana
  • Method for the selection of antibodies against BCMA
    Patent number: 9963513
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 8, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • ASPGR ANTIBODIES AND USES THEREOF
    Publication number: 20180118833
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 21, 2017
    Publication date: May 3, 2018
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas HOFER, Changhua Ji, Ekkehard Moessner, Pablo Umana
  • Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
    Patent number: 9957326
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: May 1, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Pablo Umaña, Ekkehard Mössner
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20180086849
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 29, 2018
    Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
    Patent number: 9926379
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: March 27, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20180079804
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 5, 2017
    Publication date: March 22, 2018
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • ANTI-CEA ANTIBODIES
    Publication number: 20180079827
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: June 21, 2017
    Publication date: March 22, 2018
    Applicant: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Trivalent, bispecific antibodies
    Patent number: 9890204
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
    Publication number: 20180009868
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 11, 2018
    Applicant: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker